MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis

Antonio Guasch, Carlos F Zayas Montalvo, Kamal F. Badr

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background. Leukotrienes are 5-lipoxygenated (5-LO) metabolites of arachidonic acid that mediate some of the glomerular hemodynamic and structural changes in experimental and human glomerulonephritis. Methods. We conducted an open-label, pilot study of the short-term effects of leukotriene biosynthesis inhibition using an orally active 5-LO activating protein (FLAP) antagonist (MK-591) on glomerular function in patients with glomerulonephritis. Eleven adult patients (seven women, median age 38 years) with glomerulonephritis (5 Jupus nephritis, 2 IgA nephropathy, 1 membranoproliferative, 1 membranous, 1 C1q-deficiency, and 1 idiopathic crescentic) and moderate renal insufficiency [glomerular filtration rate (GFR) 62 ± 9 ml/min/1.73 m2] were given MK-591 at a dose of 100 mg orally twice a day for four days. Results. MK-591 reduced proteinuria (albumin IgG excretion rates) from 3233 ± 1074 to 1702 ± 555 μg/min and from 196 ± 78 to 148 ± 55 μg/min for albumin and IgG respectively (P < 0.05 for both). This was not accompanied by a reduction in systemic arterial pressure, GFR, or renal plasma flow. By analysis of the fractional clearance of polydisperse , dextrans, baseline proteinuria resulted from a loss of size selectivity with enhanced passage of large (<52 Å) dextrans as compared with healthy controls. Treatment with MK-591 caused a selective improvement in the enhanced passage of large (>59 Å) dextrans without affecting the handling of smaller dextrans, indicating an improvement in glomerular size selectivity. MK-591 was well tolerated, and no adverse effects were observed. Conclusions. Short-term therapy with MK-591 reduced proteinuria by restoring glomerular size selectivity and thus reduced transglomerular protein trafficking. These benefits may result from glomerular leukotriene biosynthesis inhibition, but other MK-591-specific actions cannot be excluded.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalKidney International
Volume56
Issue number1
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

MK 0591
Glomerulonephritis
Proteinuria
Leukotrienes
Dextrans
Albumins
Immunoglobulin G
Nephritis
Protein Transport
Glomerular Filtration Rate
Arachidonic Acid
Immunoglobulin A
Renal Insufficiency
Hemodynamics

Keywords

  • Dextran sieving
  • Glomerular inflammation
  • Leukotrienes
  • Transglomerular protein trafficking

ASJC Scopus subject areas

  • Nephrology

Cite this

MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. / Guasch, Antonio; Zayas Montalvo, Carlos F; Badr, Kamal F.

In: Kidney International, Vol. 56, No. 1, 01.01.1999, p. 261-267.

Research output: Contribution to journalArticle

@article{45c317c4c44345bab212d53b131278ab,
title = "MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis",
abstract = "Background. Leukotrienes are 5-lipoxygenated (5-LO) metabolites of arachidonic acid that mediate some of the glomerular hemodynamic and structural changes in experimental and human glomerulonephritis. Methods. We conducted an open-label, pilot study of the short-term effects of leukotriene biosynthesis inhibition using an orally active 5-LO activating protein (FLAP) antagonist (MK-591) on glomerular function in patients with glomerulonephritis. Eleven adult patients (seven women, median age 38 years) with glomerulonephritis (5 Jupus nephritis, 2 IgA nephropathy, 1 membranoproliferative, 1 membranous, 1 C1q-deficiency, and 1 idiopathic crescentic) and moderate renal insufficiency [glomerular filtration rate (GFR) 62 ± 9 ml/min/1.73 m2] were given MK-591 at a dose of 100 mg orally twice a day for four days. Results. MK-591 reduced proteinuria (albumin IgG excretion rates) from 3233 ± 1074 to 1702 ± 555 μg/min and from 196 ± 78 to 148 ± 55 μg/min for albumin and IgG respectively (P < 0.05 for both). This was not accompanied by a reduction in systemic arterial pressure, GFR, or renal plasma flow. By analysis of the fractional clearance of polydisperse , dextrans, baseline proteinuria resulted from a loss of size selectivity with enhanced passage of large (<52 {\AA}) dextrans as compared with healthy controls. Treatment with MK-591 caused a selective improvement in the enhanced passage of large (>59 {\AA}) dextrans without affecting the handling of smaller dextrans, indicating an improvement in glomerular size selectivity. MK-591 was well tolerated, and no adverse effects were observed. Conclusions. Short-term therapy with MK-591 reduced proteinuria by restoring glomerular size selectivity and thus reduced transglomerular protein trafficking. These benefits may result from glomerular leukotriene biosynthesis inhibition, but other MK-591-specific actions cannot be excluded.",
keywords = "Dextran sieving, Glomerular inflammation, Leukotrienes, Transglomerular protein trafficking",
author = "Antonio Guasch and {Zayas Montalvo}, {Carlos F} and Badr, {Kamal F.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1046/j.1523-1755.1999.00537.x",
language = "English (US)",
volume = "56",
pages = "261--267",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis

AU - Guasch, Antonio

AU - Zayas Montalvo, Carlos F

AU - Badr, Kamal F.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Background. Leukotrienes are 5-lipoxygenated (5-LO) metabolites of arachidonic acid that mediate some of the glomerular hemodynamic and structural changes in experimental and human glomerulonephritis. Methods. We conducted an open-label, pilot study of the short-term effects of leukotriene biosynthesis inhibition using an orally active 5-LO activating protein (FLAP) antagonist (MK-591) on glomerular function in patients with glomerulonephritis. Eleven adult patients (seven women, median age 38 years) with glomerulonephritis (5 Jupus nephritis, 2 IgA nephropathy, 1 membranoproliferative, 1 membranous, 1 C1q-deficiency, and 1 idiopathic crescentic) and moderate renal insufficiency [glomerular filtration rate (GFR) 62 ± 9 ml/min/1.73 m2] were given MK-591 at a dose of 100 mg orally twice a day for four days. Results. MK-591 reduced proteinuria (albumin IgG excretion rates) from 3233 ± 1074 to 1702 ± 555 μg/min and from 196 ± 78 to 148 ± 55 μg/min for albumin and IgG respectively (P < 0.05 for both). This was not accompanied by a reduction in systemic arterial pressure, GFR, or renal plasma flow. By analysis of the fractional clearance of polydisperse , dextrans, baseline proteinuria resulted from a loss of size selectivity with enhanced passage of large (<52 Å) dextrans as compared with healthy controls. Treatment with MK-591 caused a selective improvement in the enhanced passage of large (>59 Å) dextrans without affecting the handling of smaller dextrans, indicating an improvement in glomerular size selectivity. MK-591 was well tolerated, and no adverse effects were observed. Conclusions. Short-term therapy with MK-591 reduced proteinuria by restoring glomerular size selectivity and thus reduced transglomerular protein trafficking. These benefits may result from glomerular leukotriene biosynthesis inhibition, but other MK-591-specific actions cannot be excluded.

AB - Background. Leukotrienes are 5-lipoxygenated (5-LO) metabolites of arachidonic acid that mediate some of the glomerular hemodynamic and structural changes in experimental and human glomerulonephritis. Methods. We conducted an open-label, pilot study of the short-term effects of leukotriene biosynthesis inhibition using an orally active 5-LO activating protein (FLAP) antagonist (MK-591) on glomerular function in patients with glomerulonephritis. Eleven adult patients (seven women, median age 38 years) with glomerulonephritis (5 Jupus nephritis, 2 IgA nephropathy, 1 membranoproliferative, 1 membranous, 1 C1q-deficiency, and 1 idiopathic crescentic) and moderate renal insufficiency [glomerular filtration rate (GFR) 62 ± 9 ml/min/1.73 m2] were given MK-591 at a dose of 100 mg orally twice a day for four days. Results. MK-591 reduced proteinuria (albumin IgG excretion rates) from 3233 ± 1074 to 1702 ± 555 μg/min and from 196 ± 78 to 148 ± 55 μg/min for albumin and IgG respectively (P < 0.05 for both). This was not accompanied by a reduction in systemic arterial pressure, GFR, or renal plasma flow. By analysis of the fractional clearance of polydisperse , dextrans, baseline proteinuria resulted from a loss of size selectivity with enhanced passage of large (<52 Å) dextrans as compared with healthy controls. Treatment with MK-591 caused a selective improvement in the enhanced passage of large (>59 Å) dextrans without affecting the handling of smaller dextrans, indicating an improvement in glomerular size selectivity. MK-591 was well tolerated, and no adverse effects were observed. Conclusions. Short-term therapy with MK-591 reduced proteinuria by restoring glomerular size selectivity and thus reduced transglomerular protein trafficking. These benefits may result from glomerular leukotriene biosynthesis inhibition, but other MK-591-specific actions cannot be excluded.

KW - Dextran sieving

KW - Glomerular inflammation

KW - Leukotrienes

KW - Transglomerular protein trafficking

UR - http://www.scopus.com/inward/record.url?scp=0033000883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033000883&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.1999.00537.x

DO - 10.1046/j.1523-1755.1999.00537.x

M3 - Article

C2 - 10411701

AN - SCOPUS:0033000883

VL - 56

SP - 261

EP - 267

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -